Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites
Phase 2
Completed
- Conditions
- Refractory Malignant Ascites
- Interventions
- Drug: Oncorine (H101)
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT04771676
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04769050
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
Recruiting
- Conditions
- Cancer
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1500
- Registration Number
- NCT04766515
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Phase 2
Recruiting
- Conditions
- NSCLC Stage IV
- Interventions
- Drug: PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)Radiation: SBRT
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 59
- Registration Number
- NCT04767009
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
Phase 2
Completed
- Conditions
- EGFR Activating MutationNSCLC Stage IV
- Interventions
- Drug: 3rd generation EGFR-TKIRadiation: Consolidative SRT
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 61
- Registration Number
- NCT04764214
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
Phase 2
Active, not recruiting
- Conditions
- Esophagus CancerChemoradiotherapyRadiation TherapyEsophageal Squamous Cell CarcinomaPostoperative
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 70
- Registration Number
- NCT04764227
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Raltitrexed in HIPEC
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 15
- Registration Number
- NCT04761185
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Procedure: biopsy or surgical pathology in metastasesDrug: 68Ga-HER2 affibody,18F-FDG, 18F-FES
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04758416
- Locations
- 🇨🇳
Shanghai Cancer Center Institutional Review Board, Shanghai, Shanghai, China
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
Phase 2
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: Personalized treatment guided by mini-PDX and RNA sequencingDrug: Nab paclitaxelDrug: EribulinDrug: VinorelbineDrug: GemcitabineDrug: Capecitabine
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04745975
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy
- Conditions
- ChemoradiotherapyNSCLCctDNA
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT04741633
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath